Home Cart Sign in  
Chemical Structure| 1206731-57-8 Chemical Structure| 1206731-57-8

Structure of WT-161
CAS No.: 1206731-57-8

Chemical Structure| 1206731-57-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

WT161 selectively inhibits HDAC6 that exhibits effective anti-tumor activities in multiple myeloma.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WT-161

CAS No. :1206731-57-8
Formula : C27H30N4O3
M.W : 458.55
SMILES Code : O=C(NO)CCCCCCC(N/N=C/C1=CC=C(N(C2=CC=CC=C2)C3=CC=CC=C3)C=C1)=O
MDL No. :MFCD31563598

Safety of WT-161

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of WT-161

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC6

    HDAC6, IC50:0.4 nM

  • HDAC2

    HDAC2, IC50:15.4 nM

  • HDAC1

    HDAC1, IC50:8.35 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
U266 cells 1, 5, 10 µM 48 hours Evaluate the effect of WT-161 on CD38 expression, results showed significant increase in CD38 expression PMC8318885
OPM-2 cells 1, 5, 10 µM 48 hours Evaluate the effect of WT-161 on CD38 expression, results showed significant increase in CD38 expression PMC8318885
MM.1S cells 1, 5, 10 µM 48 hours Evaluate the effect of WT-161 on CD38 expression, results showed significant increase in CD38 expression PMC8318885
MDA-MB231 0 - 20 µM 72 hours To evaluate the growth inhibitory effect of WT161 on MDA-MB231 cells. WT161 triggers significant growth inhibition in a dose-dependent fashion, but the sensitivity is lower. PMC5655183
BT474 0 - 20 µM 72 hours To evaluate the growth inhibitory effect of WT161 on BT474 cells. WT161 triggers significant growth inhibition in a dose-dependent fashion. PMC5655183
T47D 0 - 20 µM 72 hours To evaluate the growth inhibitory effect of WT161 on T47D cells. WT161 triggers significant growth inhibition in a dose-dependent fashion. PMC5655183
MCF7 0 - 20 µM 72 hours To evaluate the growth inhibitory effect of WT161 on MCF7 cells. WT161 triggers significant growth inhibition in a dose-dependent fashion. PMC5655183
MCF7 1 µM 8 hours To evaluate the effect of WT161 on α-tubulin acetylation in MCF7 cells. WT161 strongly increases acetylation of α-tubulin without hyperacetylation of histones. PMC5655183

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MCF7 xenograft model Intraperitoneal injection 80 mg/kg/day Daily for 3 weeks To evaluate the anti-tumor efficacy of WT161 in the MCF7 xenograft model. WT161 significantly inhibits the growth of MCF-7 xenografts, associated with downregulation of ERα. PMC5655183
Nude mice Osteosarcoma xenograft model Intraperitoneal injection 50 mg/kg Every 3 days for approximately 2 weeks To evaluate the antitumor activity of WT-161 in osteosarcoma xenograft model PMC8822767

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.90mL

2.18mL

1.09mL

21.81mL

4.36mL

2.18mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories